Stocktoria
BELITE BIO, INC BLTE
BELITE BIO, INC (BLTE) earns a Piotroski F-score of 3/9 (weak financial health). It does not currently pay a dividend.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-06-15 | HC Wainwright & Co. | Buy (reit) |
| 2026-05-26 | Mizuho | Outperform (main) |
| 2026-05-21 | HC Wainwright & Co. | Buy (reit) |
| 2026-04-22 | HC Wainwright & Co. | Buy (reit) |
| 2026-04-13 | HC Wainwright & Co. | Buy (reit) |
| 2026-03-03 | HC Wainwright & Co. | Buy (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| BLTE | BELITE BIO, INC | 3/9 | — | — | — |
| JNJ | JOHNSON & JOHNSON | 4/9 | — | 22.9 | +6% |
| LLY | ELI LILLY & Co | 7/9 | — | 55.1 | +44.7% |
| MRK | Merck & Co., Inc. | 4/9 | — | 17.4 | +1.3% |
| PFE | PFIZER INC | 4/9 | — | 17.8 | -1.6% |
| ABBV | AbbVie Inc. | 7/9 | -0.34 | 105.9 | +8.6% |
| BMY | BRISTOL MYERS SQUIBB CO | 7/9 | — | 16.7 | -0.2% |
About BELITE BIO, INC
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
FAQ
Is BLTE financially healthy?
BELITE BIO, INC's Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does BLTE pay a dividend?
No, BELITE BIO, INC does not currently pay a dividend.
How profitable is BLTE?
In FY2025, BELITE BIO, INC had a return on equity of -10.1%.
What is the analyst price target for BLTE?
The average Wall-Street price target for BELITE BIO, INC is $210.50, about 17.6% above the recent price, from 8 analysts (consensus: strong buy).
Is BLTE a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on BELITE BIO, INC: a Piotroski F-score of 3/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.